FII are selling ,DII are selling, Smart investors like Ashish Kacholia has also reduced his stake, CFO has changed, whole time director has resigned, Finance cost increased, borroiwng increasing, no concal in last quarter, sales and margin both are declining with PAT losses… but retail investors are increasing stake considering it will be a multibagger. Look at the Charts and red signals. You have other stocks also to make money …
Disclosure: Exited long back due to several red flags … Please read earlier comments
[/quote]
The company has proved to be a nothing bugger. The management cannot be relied upon at all and I have closed my position in the last quarter. The company has myriad of reasons and not tangible execution to prove its might.
Any contrarian views are invited but for now, I have stopped tracking this stock.
Lots of issues in the company - financial and others are there already and more will crop up going ahead. As a person who’s in the agrochemical industry, I’d say that it’s best to avoid this company.
a very good set of number by best agrolife business quality is improving lower invetorty and lower sales return ,margin improve & best part patented part is growing
rerating candidate completly changing of business dynamic
Financial performance for Q2 FY26 saw a decline in revenue and profitability compared to the previous year & quarter
Unfavorable and extreme weather conditions during the Kharif season were the primary reason for the decline. Heavy, untimely, and excessive rainfall led to floods, causing substantial crop damage and losses for major Kharif crops (soybean, maize, cotton, pulses)
The excessive rains reduced pest infestations and washed away the need for sprays, resulting in weak demand for agrochemicals in several regions.
The decline was expected, as the company consciously focused on optimizing inventory, streamlining channels, and aligning production with actual market demand to reduce working capital stress.
The outlook for the Rabi season is cautiously favorable and positive. Positive factors include plenty of groundwater and dams full of water, which will help the Rabi crop. The company expects volume growth to recover, driven by improved farmer sentiment and stronger demand for wheat and potato-related crop solutions.
Rabi season sales for herbicides will fall under Q3, while insecticides and fungicides sales will come in Q4.
The company is aiming for an approximate total turnover of around INR 1,500 crores for the fiscal year with 13-14% EBITDA margins
Sales returns have been reduced by more than 50% compared to last year. This is a major factor expected to drive profitability in Q3 and Q4, where traditionally the agrochemical industry experiences the bulk of sales returns. The provision made for sales returns (INR 80 crores in September) is higher than the expected actual returns (around INR 60 crores to INR 70 crores)
Inventory levels decreased by INR 207 crores year-on-year, a 24% reduction (from INR 873 crores to INR 666 crores in H1 FY26)
The company achieved an OpEx reduction of 13% compared to Q2 FY25 and 11% compared to H1 FY25. The fixed cost for a quarter is now estimated at around INR 80 crores to INR 90 crores (down from INR 100 crores average last year)
Recently launched patented products, BEST MAN, FETAGEN, and SHOT DOWN, have performed well and received good feedback.
For the next financial year (FY27), the company plans to launch a maximum of two new patented products.
The planned brownfield CapEx of approximately INR 200 crores for expansion in the Gajraula technical manufacturing unit is being delayed. The management has decided to go slow and put the project on a second priority, focusing instead on stabilizing the core business and ensuring a smooth Rabi season. They expect to start the project anywhere from 3 to 6 months.
Other Initiatives
Patented Products Focus: Patented products now contribute to more than half of the company’s brand portfolio, enhancing brand value and supporting profitability. The focus is on selling more patented products and reducing the sale of generic products and technical sales.
Intellectual Property (IP): The company added four more patents in H1 and successfully garnered a new novel nano urea patent, marking its first foray into nano materials.
International Business: Exports are a major focus area.
The company is actively working in the Africa market, expecting to do around $1 million in business with one key customer.
The China subsidiary has started generating revenue and is looked to end the year with $6 million to $8 million in revenue.
Patented product registrations are progressing in Mauritius, Sri Lanka, and Vietnam.
Technology Adoption: The company is rolling out SAP automation and analytical dashboards and is cognizant of the transformation potential of Generative AI for the Indian context.
If company is able to do the revenue of 1500cr and 13% EBITDA margin, company is likely trading at 10x FY26 earning. For FY27, assuming company would do 10% revenue growth with 14% EBITDA margins (levels which company guided for FY26 earlier), company is likely trading at 8.5x FY27 earnings. Post FY27, company’s new CAPEX plan aimed at backward integration and technicals for global markets with around ~100cr of CAPEX amount would get live; mgmt guided earlier that these products will have higher EBITDA margin profile. Overall, risk reward ratio for the company looks favorable for next 2-3 years horizon
for Q3 FY 26 Company posted Revenue of 202 Crore and Loss of 12 Crore. If we can see result we can see company have worked on OPEX and inventory levels in better way. If Stock corrects to near 15 levels in near Term I believe stock is giving Better Risk to Reward Ration.
Future Leavers -
Company is doing Technical Backward Integration in next 6 month.
They have improved on Operational expenses.
More than half revenue coming from Branded Products.
Based on my estimate this stock will perform exceptionally well in Q4 FY 26 to Q3 FY 27.
Decent quarter in tough environment; Performance was impacted by exceptionally high rainfall in October 2025 (49% above the long-period average) and erratic weather in North, West, and Central India, which disrupted cropping cycles and lower pest incidence in crops like paddy, wheat, and potatoes reduced demand for specialty products. Additionally, declining crop prices materially impacted farmers’ purchasing power.
Two newly launched patented combinations, BestMan and Fetagen, each achieved over 4 lakh treated acres in their first year.
Inventory was reduced by 24% year-on-year
The company secured new patents for several novel combination formulations, including SFP-33 and Nano-Urea.
Stock is down 80% from the high and is now trading at 30x P/E on an earning of seasonally bad year; downside looks protected
It’s seasonal. Q2 is the peak quarter for the company, which the company realize in Q3. Mgmt has also said that they are working on reducing the working capital days, both receivable as well as inventory days.